keyword
https://read.qxmd.com/read/38642158/the-endonuclease-fen1-mediates-activation-of-stat3-and-facilitates-proliferation-and-metastasis-in-breast-cancer
#21
JOURNAL ARTICLE
Min Wu, Xiaoshan Huang, Benmeng Wu, Miaolin Zhu, Yaqin Zhu, Lin Yu, Ting Lan, Jingjing Liu
BACKGROUND: The metastasis accounts for most deaths from breast cancer (BRCA). Understanding the molecular mechanisms of BRCA metastasis is urgently demanded. Flap Endonuclease 1 (FEN1), a pivotal factor in DNA metabolic pathways, contributes to tumor growth and drug resistance, however, little is known about the role of FEN1 in BRCA metastasis. METHODS AND RESULTS: In this study, FEN1 expression and its clinical correlation in BRCA were investigated using bioinformatics, showing being upregulated in BRCA samples and significant relationships with tumor stage, node metastasis, and prognosis...
April 20, 2024: Molecular Biology Reports
https://read.qxmd.com/read/38641193/intersection-of-race-rurality-and-income-in-defining-access-to-minimally-invasive-lung-surgery
#22
JOURNAL ARTICLE
J W Awori Hayanga, Xun Luo, Islam Hasasna, Paul Rothenberg, Shalini Reddy, J Hunter Mehaffey, Jason Lamb, Vinay Badhwar, Alper Toker
BACKGROUND: Race is a potent influencer of healthcare access. Geography and income may exert equal or greater influence on patient outcomes. We sought to define the intersection of race, rurality, and income and their influence on access to minimally invasive lung surgery in Medicare beneficiaries. METHODS: Medicare and Medicaid Services data were used to evaluate patients with lung cancer who underwent right upper lobectomy, via open, robotic-assisted (RATS), or video-assisted thoracic surgery (VATS) between 2018 and 2020...
April 17, 2024: Annals of Thoracic Surgery
https://read.qxmd.com/read/38640784/implantable-car-t-cell-factories-enhance-solid-tumor-treatment
#23
JOURNAL ARTICLE
Sharda Pandit, Pritha Agarwalla, Feifei Song, Anton Jansson, Gianpietro Dotti, Yevgeny Brudno
Chimeric Antigen Receptor (CAR) T cell therapy has produced revolutionary success in hematological cancers such as leukemia and lymphoma. Nonetheless, its translation to solid tumors faces challenges due to manufacturing complexities, short-lived in vivo persistence, and transient therapeutic impact. We introduce 'Drydux' - an innovative macroporous biomaterial scaffold designed for rapid, efficient in-situ generation of tumor-specific CAR T cells. Drydux expedites CAR T cell preparation with a mere three-day turnaround from patient blood collection, presenting a cost-effective, streamlined alternative to conventional methodologies...
April 15, 2024: Biomaterials
https://read.qxmd.com/read/38640748/a-phase-i-study-to-evaluate-the-safety-pharmacokinetics-and-pharmacodynamics-of-pf-06939999-prmt5-inhibitor-in-patients-with-selected-advanced-or-metastatic-tumors-with-high-incidence-of-splicing-factor-gene-mutations
#24
JOURNAL ARTICLE
J Rodon, E Rodriguez, M L Maitland, F Y-C Tsai, M A Socinski, J D Berlin, J S Thomas, T Al Baghdadi, I-M Wang, C Guo, M Golmakani, L N Clark, M Gazdoiu, M Li, A W Tolcher
BACKGROUND: Protein arginine methyltransferase 5 (PRMT5) methylates multiple substrates dysregulated in cancer, including spliceosome machinery components. PF-06939999 is a selective small-molecule PRMT5 inhibitor. PATIENTS AND METHODS: This phase I dose-escalation and -expansion trial (NCT03854227) enrolled patients with selected solid tumors. PF-06939999 was administered orally once or twice a day (q.d./b.i.d.) in 28-day cycles. The objectives were to evaluate PF-06939999 safety and tolerability to identify maximum tolerated dose (MTD) and recommended part 2 dose (RP2D), and assess pharmacokinetics (PK), pharmacodynamics [changes in plasma symmetric dimethylarginine (SDMA) levels], and antitumor activities...
April 18, 2024: ESMO Open
https://read.qxmd.com/read/38639383/peptide-transporter-1-mediated-dipeptide-transport-promotes-hepatocellular-carcinoma-metastasis-by-activating-map4k4-g3bp2-signaling-axis
#25
JOURNAL ARTICLE
Feifeng Song, Zhentao Zhang, Weifeng Liu, Tong Xu, Xiaoping Hu, Qiyue Wang, Wanli Zhang, Luqi Ge, Chengwu Zhang, Qing Hu, Hui Qin, Song Zhang, Xinxin Ren, Weijiao Fan, Yiwen Zhang, Ping Huang
Cancer metastasis is the leading cause of mortality in patients with hepatocellular carcinoma (HCC). To meet the rapid malignant growth and transformation, tumor cells dramatically increase the consumption of nutrients, such as amino acids. Peptide transporter 1 (PEPT1), a key transporter for small peptides, has been found to be an effective and energy-saving intracellular source of amino acids that are required for the growth of tumor cells. Here, the role of PEPT1 in HCC metastasis and its underlying mechanisms is explored...
April 19, 2024: Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
https://read.qxmd.com/read/38638242/assessing-the-effectiveness-and-safety-of-lenvatinib-and-everolimus-in-advanced-renal-cell-carcinoma-insights-from-the-relieve-study-s-analysis-of-heavily-pretreated-patients
#26
JOURNAL ARTICLE
Sebastiano Buti, Alessandro Olivari, Cristina Masini, Davide Bimbatti, Donata Sartori, Paola Ermacora, Carlo Cattrini, Maria Giuseppa Vitale, Ernesto Rossi, Claudia Mucciarini, Mimma Rizzo, Michele Sisani, Matteo Santoni, Giandomenico Roviello, Veronica Mollica, Vincenza Conteduca, Francesco Grillone, Marika Cinausero, Giuseppe Prati, Francesco Atzori, Marco Stellato, Francesco Massari, Melissa Bersanelli
BACKGROUND: The treatment of heavily pretreated patients with metastatic renal cell carcinoma (mRCC) represents an unmet medical need and is still challenging. OBJECTIVES: The primary objective was to assess the effectiveness of the lenvatinib plus everolimus combination and the secondary objective was the toxicity profile of this combination. DESIGN: We conducted a longitudinal retrospective study examining mRCC patients pre-treated with one or more lines of therapy among different cancer centers in Italy...
2024: Therapeutic Advances in Urology
https://read.qxmd.com/read/38637357/clinical-difference-on-the-variants-and-co-mutation-in-a-chinese-cohort-with-alk-positive-advanced-non-small-cell-lung-cancer
#27
JOURNAL ARTICLE
Ying Fu, Qing Liu, Xiaohan Wang, Liangchao Sun, Xiao Han, Xue Meng
PURPOSE: Despite the generally favourable prognoses observed in patients with ALK-positive non-small cell lung cancer (NSCLC), there remains significant variability in clinical outcomes. The objective of this study is to enhance patient stratification by examining both the specific sites of gene fusion and the presence of co-occurring mutations. METHODS: We collected retrospective clinical and pathological data on ALK-positive patients with locally advanced or metastatic disease...
April 18, 2024: Clinical & Translational Oncology
https://read.qxmd.com/read/38636250/diagnostic-yield-of-cone-beam-ct-based-navigation-bronchoscopy-in-patients-with-metastatic-lesions-a-propensity-score-matched-case-control-study
#28
JOURNAL ARTICLE
Marta Viscuso, Roel L J Verhoeven, Stephan E P Kops, Gerjon Hannink, Rocco Trisolini, Erik H F M van der Heijden
BACKGROUND: Cone beam CT based Navigation Bronchoscopy (CBCT-NB) has predominantly been investigated as a diagnostic tool in (suspected) primary lung cancers. Small metastatic lesions are clinically considered more challenging to diagnose, but no study has explored the yield of navigation bronchoscopy in patients with pulmonary metastatic lesions (ML) compared to primary lung cancers (PL), correcting for known lesion characteristics affecting diagnostic yield. MATERIALS AND METHODS: This is a single-center, retrospective, propensity score-matched case-control study...
April 15, 2024: European Journal of Surgical Oncology
https://read.qxmd.com/read/38636161/soft-tissue-tumor-of-metastatic-non-small-cell-lung-carcinoma-a-rare-case-report
#29
Andriandi, C Tirta
INTRODUCTION AND IMPORTANCE: It is estimated that 1 out of 5 patients with cancer will experience bone metastasis. With non-small cell lung cancer by itself having 220.000 reported cases per year, but the prevalence of soft tissue metastasis from lung cancer is only 2.3 % making it commonly overlooked as a possible metastasis site. CASE PRESENTATION: Male presents with a lump and pain on the right upper arm. A 8 cm × 8 cm mass was palpated under the biceps...
April 10, 2024: International Journal of Surgery Case Reports
https://read.qxmd.com/read/38634954/international-consensus-on-the-management-of-metastatic-gastric-cancer-step-by-step-in-the-foggy-landscape-bertinoro-workshop-november-2022
#30
JOURNAL ARTICLE
Paolo Morgagni, Maria Bencivenga, Fatima Carneiro, Stefano Cascinu, Sarah Derks, Maria Di Bartolomeo, Claire Donohoe, Clarisse Eveno, Suzanne Gisbertz, Peter Grimminger, Ines Gockel, Heike Grabsh, Paulo Kassab, Rupert Langer, Sara Lonardi, Marco Maltoni, Sheraz Markar, Markus Moehler, Daniele Marrelli, Maria Antonietta Mazzei, Davide Melisi, Carlo Milandri, Paul Stefan Moenig, Bianca Mostert, Gianni Mura, Wojciech Polkowski, John Reynolds, Luca Saragoni, Mark I Van Berge Henegouwen, Richard Van Hillegersberg, Michael Vieth, Giuseppe Verlato, Lorena Torroni, Bas Wijnhoven, Guido Alberto Massimo Tiberio, Han-Kwang Yang, Franco Roviello, Giovanni de Manzoni
BACKGROUND: Many gastric cancer patients in Western countries are diagnosed as metastatic with a median overall survival of less than twelve months using standard chemotherapy. Innovative treatments, like targeted therapy or immunotherapy, have recently proved to ameliorate prognosis, but a general agreement on managing oligometastatic disease has yet to be achieved. An international multi-disciplinary workshop was held in Bertinoro, Italy, in November 2022 to verify whether achieving a consensus on at least some topics was possible...
April 18, 2024: Gastric Cancer
https://read.qxmd.com/read/38633838/microcomputed-tomography-as-a-diagnostic-tool-for-detection-of-lymph-node-metastasis-in-non-small-cell-lung-cancer-a-decision-support-approach-for-pathological-examination-a-pilot-study-for-method-validation
#31
JOURNAL ARTICLE
Ayten Kayı Cangır, Süleyman Gökalp Güneş, Kaan Orhan, Hilal Özakıncı, Yusuf Kahya, Duru Karasoy, Serpil Dizbay Sak
BACKGROUND: Non-small cell lung cancer (NSCLC) patients without lymph node (LN) metastases (pN0) may exhibit different survival rates, even when their T stage is similar. This divergence could be attributed to the current pathology practice, wherein LNs are examined solely in two-dimensional (2D). Unfortunately, adhering to the protocols of 2D pathological examination does not ensure the exhaustive sampling of all excised LNs, thereby leaving room for undetected metastatic foci in the unexplored depths of tissues...
December 2024: Journal of Pathology Informatics
https://read.qxmd.com/read/38633674/molecular-profiling-of-primary-endometrioid-endometrial-cancer-and-matched-lung-metastases-ctnnb1-mutation-as-a-potential-driver
#32
Sushmita Gordhandas, Arnaud Da Cruz Paula, Elizabeth C Kertowidjojo, Fresia Pareja, Kimberly Dessources, Edaise M da Silva, Fatemeh Derakhshan, Jennifer J Mueller, Nadeem R Abu-Rustum, M Herman Chui, Britta Weigelt
•Both primary endometrial cancers (ECs) and matched lung metastases shared a common ancestor with independent evolution at each site.•The two endometrioid ECs studied acquired additional mutations during the distant metastatic process.•Subclonal CTNNB1 hotspot mutations in the two primary ECs studied became clonal in the distant metastases.
June 2024: Gynecologic Oncology Reports
https://read.qxmd.com/read/38632190/establishment-and-characterization-of-novel-high-mucus-producing-lung-tumoroids-derived-from-a-patient-with-pulmonary-solid-adenocarcinoma
#33
JOURNAL ARTICLE
Miki Iwai, Etsuko Yokota, Yuta Ishida, Takuro Yukawa, Yoshio Naomoto, Yasumasa Monobe, Minoru Haisa, Nagio Takigawa, Takuya Fukazawa, Tomoki Yamatsuji
Among mucus-producing lung cancers, invasive mucinous adenocarcinoma of the lung is a rare and unique subtype of pulmonary adenocarcinoma. Notably, mucus production may also be observed in the five subtypes of adenocarcinoma grouped under the higher-level diagnosis of Invasive Non-mucinous Adenocarcinomas (NMA). Overlapping pathologic features in mucus-producing tumors can cause diagnostic confusion with significant clinical consequences. In this study, we established lung tumoroids, PDT-LUAD#99, from a patient with NMA and mucus production...
April 17, 2024: Human Cell
https://read.qxmd.com/read/38631192/gastric-outlet-obstruction-as-a-presentation-of-metastatic-squamous-cell-carcinoma-of-the-bladder-a-case-report-and-review-of-the-literature
#34
Jana H Mahdi, Baraa AlJardali, Oussama G Nasrallah, Noura El Sayegh, Marwan Zein, Rami W Nasr
INTRODUCTION: Gastric outlet obstruction presents with a range of symptoms which include abdominal pain, early satiety, weight loss and vomiting caused obstruction secondary to tumors from outside the gastrointestinal tract or due to motility disorders. Bladder cancer is rarely associated with Gastric outlet obstruction. It usually presents with painless hematuria and urinary symptoms. Squamous cell carcinoma is a subtype of bladder malignancies that tends to present at a later stage and is associated with poorer prognosis in terms of metastasis and survival...
April 9, 2024: International Journal of Surgery Case Reports
https://read.qxmd.com/read/38630893/small-extracellular-vesicles-promote-stiffness-mediated-metastasis
#35
JOURNAL ARTICLE
Alexandra Sneider, Ying Liu, Bartholomew Starich, Wenxuan Du, Praful R Nair, Carolyn Marar, Najwa Faqih, Gabrielle E Ciotti, Joo Ho Kim, Sejal Krishnan, Salma Ibrahim, Muna Igboko, Alexus Locke, Daniel M Lewis, Hanna Hong, Michelle N Karl, Raghav Vij, Gabriella C Russo, Estibaliz Gómez-de-Mariscal, Mehran Habibi, Arrate Muñoz-Barrutia, Luo Gu, T S Karin Eisinger-Mathason, Denis Wirtz
Tissue stiffness is a critical prognostic factor in breast cancer and is associated with metastatic progression. Here we show an alternative and complementary hypothesis of tumor progression whereby physiological matrix stiffness affects the quantity and protein cargo of small EVs produced by cancer cells, which in turn aid cancer cell dissemination. Primary patient breast tissue produces significantly more EVs from stiff tumor tissue than soft tumor adjacent tissue. EVs released by cancer cells on matrices that model human breast tumors (25 kPa; stiff EVs) feature increased adhesion molecule presentation (ITGα2β1, ITGα6β4, ITGα6β1, CD44) compared to EVs from softer normal tissue (0...
April 17, 2024: Cancer Res Commun
https://read.qxmd.com/read/38629624/single-cell-transcriptomics-reveal-metastatic-cldn4-cancer-cells-underlying-the-recurrence-of-malignant-pleural-effusion-in-patients-with-advanced-non-small-cell-lung-cancer
#36
JOURNAL ARTICLE
Xiaoshen Zhang, Xuanhe Wang, Yaokai Wen, Shen Chen, Caicun Zhou, Fengying Wu
BACKGROUND: Recurrent malignant pleural effusion (MPE) resulting from non-small-cell lung cancer (NSCLC) is easily refractory to conventional therapeutics and lacks predictive markers. The cellular or genetic signatures of recurrent MPE still remain largely uncertain. METHODS: 16 NSCLC patients with pleural effusions were recruited, followed by corresponding treatments based on primary tumours. Non-recurrent or recurrent MPE was determined after 3-6 weeks of treatments...
April 2024: Clinical and Translational Medicine
https://read.qxmd.com/read/38628329/sarcoidosis-presenting-as-multiple-osseous-lesions
#37
Maryam Riaz, Swastika Jha
Sarcoidosis is a multisystem inflammatory condition presenting with the formation of noncaseating granulomas. These granulomas can be found in nearly every organ of the body, but in 90% of cases the lungs are involved. Osseous manifestations are seen in only 3% to 13% of cases and are typically seen alongside the more common pulmonary manifestations. These lesions can be misdiagnosed as metastatic cancer so biopsy, along with clinical correlation and exclusion of other diseases, is necessary to make the diagnosis...
2024: Proceedings of the Baylor University Medical Center
https://read.qxmd.com/read/38627967/switch-of-elf3-and-atf4-transcriptional-axis-programs-the-amino-acid-insufficiency-linked-epithelial-to-mesenchymal-transition
#38
JOURNAL ARTICLE
Jianxiang Lin, Linjun Hou, Xin Zhao, Jingli Zhong, Yilv Lv, Xiaohua Jiang, Bo Ye, Yunbo Qiao
Epithelial-to-mesenchymal transition (EMT) that endows cancer cells with increased invasive and migratory capacity enables cancer dissemination and metastasis. This process is tightly associated with metabolic reprogramming acquired for rewiring cell status and signaling pathways for survival in dietary insufficiency conditions. However, it remains largely unclear how transcription factor (TF)-mediated transcriptional programs are modulated during the EMT process. Here we reveal that depletion of a key epithelial TF, ELF3, triggers a TGFβ signaling activation-like mesenchymal transcriptomic profile and metastatic features linked to the aminoacyl-tRNA biogenesis pathway...
April 15, 2024: Molecular Therapy
https://read.qxmd.com/read/38627902/extrapleural-pneumonectomy-for-sarcoma-outcomes-of-adult-patients-at-a-specialized-center
#39
JOURNAL ARTICLE
Betty Y Zhang, Ashley R Wilson-Smith, Elizabeth A Connolly, Madeleine C Strach, Nathan Ussher, Tristan Yan, Vivek A Bhadri
BACKGROUND: Extrapleural pneumonectomy (EPP) is a complex surgical procedure involving en-bloc resection of the parietal and visceral pleura, lung, pericardium, and ipsilateral diaphragm. Small case series of pleural-based sarcoma of predominantly pediatric patients suggest EPP may be a life-prolonging surgical option. We aimed to describe the characteristics and outcomes of adults who underwent EPP at a specialized sarcoma center. METHODS: Clinicopathologic variables, surgical details, and follow-up information were extracted for patients undergoing EPP for pleural-based sarcoma between August 2017 and December 2020...
April 2024: Cancer reports
https://read.qxmd.com/read/38627519/co-clustering-of-ephb6-and-ephrinb1-in-trans-restrains-cancer-cell-invasion
#40
JOURNAL ARTICLE
Lung-Yu Liang, Niall D Geoghegan, Michael Mlodzianoski, Andrew Leis, Lachlan W Whitehead, Minglyanna G Surudoi, Samuel N Young, Peter Janes, Doulin Shepherd, Debnath Ghosal, Kelly L Rogers, James M Murphy, Isabelle S Lucet
EphB6 is an understudied ephrin receptor tyrosine pseudokinase that is downregulated in multiple types of metastatic cancers. Unlike its kinase-active counterparts which autophosphorylate and transmit signals upon intercellular interaction, little is known about how EphB6 functions in the absence of intrinsic kinase activity. Here, we unveil a molecular mechanism of cell-cell interaction driven by EphB6. We identify ephrinB1 as a cognate ligand of EphB6 and show that in trans interaction of EphB6 with ephrinB1 on neighboring cells leads to the formation of large co-clusters at the plasma membrane...
April 16, 2024: Communications Biology
keyword
keyword
36942
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.